AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

October 7, 2019

Study Completion Date

October 7, 2019

Conditions
Antiphospholipid Syndrome in PregnancyPregnancy Loss
Interventions
DRUG

Aspirin 81 mg

Aspirin 81 mg po daily in tablet form.

DRUG

Low-molecular-weight heparin

The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.

Trial Locations (1)

Unknown

Ottawa Hospital Research Institute, Ottawa

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER